STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program

Leaders at the FDA held a listening session on the Commissioner’s National Priority Voucher program, which offers expedited drug reviews for companies aligning with vague national priorities. While some speakers supported the program, most urged the FDA to pause it and restart through standard regulatory processes due to concerns about political interference.